Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

European approval for Portrazza for advanced squamous NSCLC

Feb. 16, 2016

PDS Biotechnology and NCI to codevelop novel cancer immunotherapies

Feb. 15, 2016

Patient with B-cell lymphoma in remission following treatment with OXS-1550

Feb. 11, 2016

SymBio and Teikyo Heisei University collaborate to develop TTR1 therapeutic anticancer drug

Feb. 11, 2016

FDA lifts partial clinical hold on vesigenurtucel-L

Feb. 11, 2016

Phase I data support progression of Immune Design's immuno-oncology candidates

Feb. 10, 2016

Adaptimmune's NY-ESO T-cell therapy earns FDA breakthrough therapy designation

Feb. 10, 2016

PDS Biotechnology and NCI to codevelop novel cancer immunotherapies

Feb. 10, 2016

OncoMed gives update on ALPINE and PINNACLE studies of tarextumab

Feb. 10, 2016

EBV-CTL granted U.S. orphan status for EBV-positive post-transplant lymphoproliferative disorders

Feb. 8, 2016

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...